Moderna : Attentes 2024 confirmées, une montée en douceur du vaccin RSV
>T3 supérieur aux attentes grâce à une saison de vaccination COVID plus précoce - Malgré un T3 qualitatif, le titre est resté sous pression en fin de semaine du fait d’une montée en puissance plus lente qu’anticipé de son vaccin contre le RSV, d’un lancement commercial de son vaccin COVID/grippe saisonnière prévu plutôt pour la saison 2026 et évidemment des questionnements sur le positionnement du futur gouvernement américain sur les programmes de vaccinations. Briève...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.